Skip to content

Study · Randomized controlled trial · n = 1,637 · 2015

6 results

FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.

Harvey NC, Kanis JA, Odén A, Burge RT, Mitlak BH, Johansson H, McCloskey EV

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA20 Jun 2015Cited by 32 (Europe PMC)

PMID26092063 (opens in a new tab)PMCIDPMC4913866 (opens in a new tab)DOI10.1007/s00198-015-3173-3 (opens in a new tab)PepBankPUB-26092063
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, pooled teriparatide doses reduced all non-vertebral fractures by 37% versus placebo.

    In plain wordsIn postmenopausal women, teriparatide reduced fractures outside the spine compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseAll non-vertebral fractures
    Study

    n = 1,637

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 μg daily, pooled · injectionAs given in this study (human).

    Measurements

    Relative fracture reduction
    37%
    all non-vertebral, versus placebo

    Source sentences

    Summary
    Treatment with teriparatide was associated with a 37 % decrease in all non-vertebral fractures (95 % CI 10-56 %) and a 56 % decrease in low-energy non-vertebral fractures (95 % CI 24-75 %) compared with placebo.
    2 context sentences
    Summary · context
    One thousand six hundred thirty-seven postmenopausal women in the pivotal phase three trial, randomly assigned to receive placebo (n = 544), teriparatide 20 μg per day (n = 541) or teriparatide 40 μg per day (n = 552), were studied.
    Summary · context
    Because there was no difference in effect of 20 and 40 μg teriparatide daily on fracture occurrence, the two active groups were merged.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, pooled teriparatide doses reduced low-energy non-vertebral fractures by 56% versus placebo.

    In plain wordsIn postmenopausal women, teriparatide reduced low-energy fractures outside the spine compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseLow-energy non-vertebral fractures
    Study

    n = 1,637

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 μg daily, pooled · injectionAs given in this study (human).

    Measurements

    Relative fracture reduction
    56%
    low-energy non-vertebral, versus placebo

    Source sentences

    Summary
    Treatment with teriparatide was associated with a 37 % decrease in all non-vertebral fractures (95 % CI 10-56 %) and a 56 % decrease in low-energy non-vertebral fractures (95 % CI 24-75 %) compared with placebo.
    2 context sentences
    Summary · context
    One thousand six hundred thirty-seven postmenopausal women in the pivotal phase three trial, randomly assigned to receive placebo (n = 544), teriparatide 20 μg per day (n = 541) or teriparatide 40 μg per day (n = 552), were studied.
    Summary · context
    Because there was no difference in effect of 20 and 40 μg teriparatide daily on fracture occurrence, the two active groups were merged.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, pooled teriparatide doses reduced morphometric vertebral fracture risk by 66% versus placebo.

    In plain wordsIn postmenopausal women, teriparatide reduced spine fractures detected by measurement compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseMorphometric vertebral fractures
    Study

    n = 1,637

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 μg daily, pooled · injectionAs given in this study (human).

    Measurements

    Relative fracture reduction
    66%
    morphometric vertebral

    Source sentences

    Summary
    The risk of morphometric vertebral fractures decreased significantly by 66 % (95 % CI 50-77 %).
    2 context sentences
    Summary · context
    One thousand six hundred thirty-seven postmenopausal women in the pivotal phase three trial, randomly assigned to receive placebo (n = 544), teriparatide 20 μg per day (n = 541) or teriparatide 40 μg per day (n = 552), were studied.
    Summary · context
    Because there was no difference in effect of 20 and 40 μg teriparatide daily on fracture occurrence, the two active groups were merged.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, fracture occurrence did not differ between teriparatide doses, so the active groups were merged.

    In plain wordsIn postmenopausal women, fracture occurrence did not differ between the two teriparatide doses.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFracture occurrence by teriparatide dose
    Study

    n: not reported in source

    Comparator
    Teriparatide 20 versus 40 μg daily
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 μg daily, pooled · injectionAs given in this study (human).

    Source sentences

    Summary
    Because there was no difference in effect of 20 and 40 μg teriparatide daily on fracture occurrence, the two active groups were merged.
    1 context sentence
    Summary · context
    One thousand six hundred thirty-seven postmenopausal women in the pivotal phase three trial, randomly assigned to receive placebo (n = 544), teriparatide 20 μg per day (n = 541) or teriparatide 40 μg per day (n = 552), were studied.

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In postmenopausal women, teriparatide fracture hazard ratios versus placebo did not change significantly with increasing baseline fracture probability.

    In plain wordsIn postmenopausal women, teriparatide's fracture reduction versus placebo did not differ significantly across baseline fracture probabilities.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFracture probability interaction with efficacy
    Study

    n = 1,637

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Hazard ratios for the effect of teriparatide on the fracture outcome did not change significantly with increasing fracture probability (p > 0.30).
    2 context sentences
    Summary · context
    One thousand six hundred thirty-seven postmenopausal women in the pivotal phase three trial, randomly assigned to receive placebo (n = 544), teriparatide 20 μg per day (n = 541) or teriparatide 40 μg per day (n = 552), were studied.
    Summary · context
    Because there was no difference in effect of 20 and 40 μg teriparatide daily on fracture occurrence, the two active groups were merged.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In postmenopausal women, the absence of a significant interaction between baseline fracture probability and teriparatide efficacy versus placebo was similar when BMD was excluded from FRAX or when hip fracture probability was used.

    In plain wordsIn women, teriparatide's fracture reduction over placebo did not differ significantly by baseline risk, with bone density left out or with hip fracture risk used.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeEfficacy interaction in FRAX sensitivity analyses (BMD excluded; hip fracture probability)
    Study

    n = 1,637

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Similar findings were noted for the interaction when BMD was excluded from the FRAX model, or when probability of hip fracture was used as the marker of baseline risk.
    3 context sentences
    Summary · context
    Hazard ratios for the effect of teriparatide on the fracture outcome did not change significantly with increasing fracture probability (p > 0.30).
    Summary · context
    One thousand six hundred thirty-seven postmenopausal women in the pivotal phase three trial, randomly assigned to receive placebo (n = 544), teriparatide 20 μg per day (n = 541) or teriparatide 40 μg per day (n = 552), were studied.
    Summary · context
    Because there was no difference in effect of 20 and 40 μg teriparatide daily on fracture occurrence, the two active groups were merged.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.